| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2025 | IRWD Ironwood Pharmaceuticals Inc | Martini Gregory S. | Chief Financial Officer | Sell | 12,052 | $1.76 | $21,211.52 | -6.2% | -58.5% | +159.3% | |
| Feb 10, 2025 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 38,938 | $1.76 | $68,530.88 | -8.7% | -58.5% | +159.3% | |
| Feb 10, 2025 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $348.06 | $3,480,642.28 | -34.9% | -10.1% | +36.9% | |
| Feb 10, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 14,000 | $19.57 | $273,980.00 | -14.6% | +36.9% | +128.1% | |
| Feb 10, 2025 | IRWD Ironwood Pharmaceuticals Inc | McCourt Thomas A66 | Chief Executive Officer | Sell | 139,064 | $1.76 | $244,752.64 | -10.7% | -58.5% | +159.3% | |
| Feb 10, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $43.01 | $498,100.46 | -3.4% | +23.3% | -61.5% | |
| Feb 10, 2025 | IRWD Ironwood Pharmaceuticals Inc | Shetzline Michael67 | SVP, CMO, Head-res&Drug | Sell | 41,269 | $1.76 | $72,633.44 | -6.9% | -58.5% | +159.3% | |
| Feb 10, 2025 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 7,259 | $43.28 | $314,169.52 | -3.6% | +23.3% | -61.5% | |
| Feb 10, 2025 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 12,048 | $1.76 | $21,204.48 | -4.1% | -58.5% | +159.3% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 700 | $118.28 | $82,792.50 | -3.6% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 700 | $118.31 | $82,820.08 | -25.9% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Executive Officer | Sell | 980 | $118.39 | $116,020.34 | -0.7% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 980 | $118.31 | $115,940.37 | -2.2% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles56 | Director | Sell | 2,274 | $118.37 | $269,167.24 | -0.4% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 980 | $118.22 | $115,852.66 | -2.9% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 911 | $118.25 | $107,727.03 | -2.1% | +1.4% | +15.9% | |
| Feb 10, 2025 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 980 | $118.27 | $115,908.52 | -2.8% | +1.4% | +15.9% | |
| Feb 7, 2025 | JNJ Johnson & Johnson | Wolk Joseph J | Exec VP, CFO | Sell | 13,015 | $153.89 | $2,002,878.35 | -100% | +1.7% | +56.7% | |
| Feb 6, 2025 | MRK Merck & Co., Inc. | Downing Cristal N | Chief Comm. &Public Afrs Ofcr | Sell | 2,361 | $88.76 | $209,550.79 | -25.0% | -10.1% | +38.5% | |
| Feb 6, 2025 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $874.13 | $183,567,261.66 | - | -10.8% | +21.6% | |
| Feb 6, 2025 | MRK Merck & Co., Inc. | Thulin Inge G | Director | Buy | 2,833 | $88.25 | $249,999.98 | +2,833% | -10.1% | +38.5% | |
| Feb 5, 2025 | MRK Merck & Co., Inc. | Baker Douglas M Jr | Director | Buy | 15,000 | $88.50 | $1,327,500.00 | +1,500% | -11.9% | +33.5% | |
| Feb 4, 2025 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $38.92 | $450,730.07 | -2.5% | +0.1% | -41.7% | |
| Feb 4, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 9,477 | $39.70 | $376,236.90 | -48.3% | -19.0% | +22.7% | |
| Feb 3, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 11,851 | $3.47 | $41,107.56 | -0.4% | +50.6% | +323.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.